Karachi: Liven Pharma Limited released its annual financial statement for the fiscal year ending on June 30, 2026, showing a significant increase in total assets and a narrowed net loss. The report, dated October 5, 2026, provides insight into the company's financial health and strategic investments over the past year.

The pharmaceutical company reported total assets of 1.22 billion rupees, a substantial increase from the previous year's 822.90 million rupees. This growth was largely attributed to an increase in non-current assets, which rose to 922.96 million rupees from 674.95 million rupees, primarily driven by investments in property, plant, and equipment.

The total equity surged to 985.46 million rupees from 633.86 million rupees, supported by an increase in issued, subscribed, and paid-up share capital, which reached 1.13 billion rupees. The company's revenue reserve, however, continued to reflect an accumulated loss, which expanded to 333.86 million rupees from 296.54 million rupees in the previous year.

According to information available from the Pakistan Stock Exchange (PSX), Liven Pharma's sales for the year stood at 105.81 million rupees, a decrease from the prior year's 127.27 million rupees, marking a very large or significant move. The cost of sales also fell, resulting in a gross profit of 26.65 million rupees, up from 17.96 million rupees, reflecting the company's efforts to improve operational efficiency.

Despite the increase in gross profit, administrative and general expenses were recorded at 37.71 million rupees, along with selling and distribution expenses of 9.76 million rupees. Other expenses amounted to 53.77 million rupees, while finance costs increased to 2.54 million rupees. Consequently, the operating loss was reduced to 77.14 million rupees from the previous year's 490.90 million rupees.

Liven Pharma reported a loss before taxation of 66.32 million rupees, a significant improvement from last year's 492.19 million rupees loss. The taxation benefit of 35.18 million rupees contributed to narrowing the net loss after taxation to 31.14 million rupees, in comparison to the prior year's 584.46 million rupees.

The company's liabilities also increased, with non-current liabilities rising to 119.31 million rupees and current liabilities reaching 111.27 million rupees. The total liabilities amounted to 230.58 million rupees, up from 189.04 million rupees the previous year.

With these financial results, Liven Pharma Limited continues to focus on asset expansion and strategic investments, aiming to position itself for future growth in the pharmaceutical sector.